Medical Treatment of Hepatorenal Syndrome - AASLD

More documents

Recommendations

Info

Survival DistributionFunction1.00.90.80.70.60.50.40.30.20.10.0P-value:Impact <strong>of</strong> Reversal <strong>of</strong> HRS onTransplant-Free Survival0 14(0.001)30(0.004)60(0.003)Survival (Days)90(0.001)= Censored = HRS Reversal = No HRS Reversal
Survival DistributionFunction1.00.90.80.70.60.50.40.30.20.10.0P-value:Transplant-Free Survival 90 Days0 14(0.875)30(0.477)60(0.991)Survival (Days)= Censored = Terlipressin = Placebo90(0.784)
Page 1 and 2: Thomas D. Boyer, MDHepatorenal Synd
Page 3 and 4: Conflicts of interest• Member adv
Page 5 and 6: Pathogenesis of Ascites in Cirrhosi
Page 7 and 8: 7060504030252015105Neurohumoral Sys
Page 9 and 10: Type and Frequency of Injury inAcut
Page 11: Workup of Renal Dysfunction in Pati
Page 14 and 15: Hepatorenal syndromeAdditional Crit
Page 16 and 17: Type 1 HRS Is Associated WithVery P
Page 18 and 19: Who Develops HRS?•Cirrhotic patie
Page 20 and 21: Prevention of HRS
Page 22 and 23: Antibiotic Prophylaxis in VaricealB
Page 24 and 25: Prostaglandin Inhibition andEffects
Page 26 and 27: Treatment of HRS General• Stop al
Page 28 and 29: Site of Action of CurrentTherapies
Page 30 and 31: TIPS and HRSGut 47:166; 2000
Page 32 and 33: Treatment of HRS:Pharmacologic Ther
Page 34 and 35: Background (II)• Synthetic 12-ami
Page 36 and 37: Reversal of HRS40HRS Reversal (%)30
Page 40 and 41: Adverse EventsTerlipressinN=56Place
Page 42 and 43: Impact of OLTx on RenalGlomerular f
Page 44 and 45: HRS conclusions continued• Exclus

Medical Treatment of Hepatorenal Syndrome - AASLD

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?